secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002587
Event type: other
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022
--------------------------------------------------------------------------------

- FDA allowed IND application for BDTX-1535 on January 10, 2022.
- Phase 1 study of BDTX-1535 to begin in Q1 2022.
- Company expects to provide a clinical update in the second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/0001104659-22-002587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/tm222372d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer